| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1041627677 |
| P356 | DOI | 10.1038/NRG3742 |
| P932 | PMC publication ID | 4393649 |
| P698 | PubMed publication ID | 24840552 |
| P50 | author | David Schaffer | Q59749936 |
| P2093 | author name string | Melissa A Kotterman | |
| P2860 | cites work | A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Müller cells | Q21142728 |
| Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions | Q24531466 | ||
| The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. | Q24533492 | ||
| Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients | Q83720294 | ||
| Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial | Q24608049 | ||
| Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease | Q24626259 | ||
| A viral assembly factor promotes AAV2 capsid formation in the nucleolus | Q24630650 | ||
| Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1 | Q24634560 | ||
| Safety and efficacy of gene transfer for Leber's congenital amaurosis | Q24634724 | ||
| Directed evolution of adeno-associated virus to an infectious respiratory virus | Q24649385 | ||
| Structural Insight into the Unique Properties of Adeno-Associated Virus Serotype 9 | Q27678476 | ||
| Structural Insights into Adeno-Associated Virus Serotype 5 | Q27679454 | ||
| In vivo genome editing restores haemostasis in a mouse model of haemophilia | Q28241725 | ||
| Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial | Q28262431 | ||
| Effect of gene therapy on visual function in Leber's congenital amaurosis | Q28277981 | ||
| Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. | Q28306059 | ||
| ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering | Q29615505 | ||
| Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
| Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years | Q30537764 | ||
| AAV2 gene therapy readministration in three adults with congenital blindness. | Q30587265 | ||
| Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection | Q30923081 | ||
| Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors | Q30975099 | ||
| In vitro selection of viral vectors with modified tropism: the adeno-associated virus display | Q33187644 | ||
| Directed evolution of adeno-associated virus yields enhanced gene delivery vectors | Q33232270 | ||
| Adeno-associated virus serotypes: vector toolkit for human gene therapy | Q33249130 | ||
| Isolation of targeted AAV2 vectors from novel virus display libraries | Q33256517 | ||
| Engineering adeno-associated virus for one-step purification via immobilized metal affinity chromatography | Q33282204 | ||
| Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy | Q33301839 | ||
| In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses | Q33327474 | ||
| Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles | Q33337378 | ||
| Molecular engineering of viral gene delivery vehicles | Q33353795 | ||
| DNA shuffling of adeno-associated virus yields functionally diverse viral progeny | Q33363531 | ||
| A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection | Q33411254 | ||
| Molecular evolution of adeno-associated virus for enhanced glial gene delivery | Q33492733 | ||
| Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). | Q33521174 | ||
| Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency | Q33567468 | ||
| Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous | Q33622746 | ||
| Effect of genome size on AAV vector packaging | Q33730405 | ||
| An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells | Q33790771 | ||
| Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors | Q34034500 | ||
| Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells | Q34080512 | ||
| Directed evolution of novel adeno-associated viruses for therapeutic gene delivery. | Q34188892 | ||
| Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure | Q34195822 | ||
| Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs. | Q35174932 | ||
| The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes | Q35531575 | ||
| Adenovirus-associated virus vector-mediated gene transfer in hemophilia B | Q35691659 | ||
| Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors | Q35712206 | ||
| Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector | Q36663364 | ||
| Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses | Q36685842 | ||
| Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. | Q36709834 | ||
| CpG-depleted adeno-associated virus vectors evade immune detection. | Q36966955 | ||
| Expanding adeno-associated viral vector capacity: a tale of two vectors. | Q37024689 | ||
| Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression | Q37098067 | ||
| Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy | Q37111962 | ||
| Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency | Q37213826 | ||
| Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. | Q37364786 | ||
| Effective delivery of large genes to the retina by dual AAV vectors | Q37591108 | ||
| Selection and evaluation of clinically relevant AAV variants in a xenograft liver model | Q37610916 | ||
| CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome. | Q37690476 | ||
| Rare-disease genetics in the era of next-generation sequencing: discovery to translation | Q38133704 | ||
| AAV mediated GDNF secretion from retinal glia slows down retinal degeneration in a rat model of retinitis pigmentosa | Q38585967 | ||
| Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure | Q39589248 | ||
| Marker rescue of adeno-associated virus (AAV) capsid mutants: a novel approach for chimeric AAV production | Q39698557 | ||
| Human gene targeting by viral vectors | Q41480639 | ||
| Overcoming preexisting humoral immunity to AAV using capsid decoys | Q42056009 | ||
| Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization | Q42203239 | ||
| Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors | Q42235082 | ||
| Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer | Q42541148 | ||
| Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients | Q43466855 | ||
| Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors | Q44258968 | ||
| In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous | Q45350780 | ||
| CD8(+) T-cell responses to adeno-associated virus capsid in humans | Q45406111 | ||
| Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus | Q45422552 | ||
| Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. | Q45887588 | ||
| Transposon-based mutagenesis generates diverse adeno-associated viral libraries with novel gene delivery properties | Q46583999 | ||
| Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles | Q56897778 | ||
| P433 | issue | 7 | |
| P921 | main subject | gene therapy | Q213901 |
| P304 | page(s) | 445-451 | |
| P577 | publication date | 2014-05-20 | |
| P1433 | published in | Nature Reviews Genetics | Q1071824 |
| P1476 | title | Engineering adeno-associated viruses for clinical gene therapy | |
| P478 | volume | 15 |
| Q40532321 | A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons |
| Q55508466 | A Recombinant Baculovirus Efficiently Generates Recombinant Adeno-Associated Virus Vectors in Cultured Insect Cells and Larvae. |
| Q40207901 | A Scalable and Accurate Method for Quantifying Vector Genomes of Recombinant Adeno-Associated Viruses in Crude Lysate. |
| Q90049700 | A Student's Guide to Neural Circuit Tracing |
| Q88808515 | A Universal GSH-Responsive Nanoplatform for the Delivery of DNA, mRNA, and Cas9/sgRNA Ribonucleoprotein |
| Q42366746 | A compact unc45b-promoter drives muscle-specific expression in zebrafish and mouse |
| Q28066790 | A lncRNA Perspective into (Re)Building the Heart |
| Q90283465 | A method for gene knockdown in the retina using a lipid-based carrier |
| Q27340016 | A new design for a green calcium indicator with a smaller size and a reduced number of calcium-binding sites |
| Q55620891 | A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency. |
| Q37696772 | A viral strategy for targeting and manipulating interneurons across vertebrate species. |
| Q92186150 | AAV GCG-EGFP, a new tool to identify glucagon-secreting α-cells |
| Q35695082 | AAV ancestral reconstruction library enables selection of broadly infectious viral variants. |
| Q90531372 | AAV diffuses across zona pellucida for effortless gene delivery to fertilized eggs |
| Q35594880 | AAV's Golden Jubilee |
| Q35483517 | AAV-8 is more efficient than AAV-9 in transducing neonatal dog heart. |
| Q40419332 | AAV-Mediated Anterograde Transsynaptic Tagging: Mapping Corticocollicular Input-Defined Neural Pathways for Defense Behaviors |
| Q89981372 | AAV-expressed G protein induces robust humoral and cellular immune response and provides durable protection from rabies virus challenges in mice |
| Q40644305 | Adeno Associated Virus 9-Based Gene Therapy Delivers a Functional Monocarboxylate Transporter 8, Improving Thyroid Hormone Availability to the Brain of Mct8-Deficient Mice. |
| Q92345084 | Adeno-Associated Viral Vectors in Neuroscience Research |
| Q39409371 | Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. |
| Q38797808 | Adeno-Associated Virus 5 Transduces Adipose-Derived Stem Cells with Greater Efficacy Than Other Adeno-Associated Viral Serotypes |
| Q34047590 | Adeno-Associated Virus-Mediated Delivery of CRISPR-Cas Systems for Genome Engineering in Mammalian Cells. |
| Q57492577 | Adeno-Associated Virus-Mediated RNAi against Mutant Alleles Attenuates Abnormal Calvarial Phenotypes in an Apert Syndrome Mouse Model |
| Q38706321 | Adeno-associated virus (AAV) vectors in cancer gene therapy. |
| Q91451131 | Adeno-associated virus 2 bound to its cellular receptor AAVR |
| Q57062356 | Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1 |
| Q37571229 | Adeno-associated virus serotype rh.10 displays strong muscle tropism following intraperitoneal delivery |
| Q64040883 | Adeno-associated virus vector as a platform for gene therapy delivery |
| Q88599910 | Advances in Biomaterials for Drug Delivery |
| Q38706445 | Advances in the delivery of RNA therapeutics: from concept to clinical reality. |
| Q38601075 | Advances in treatment of achondroplasia and osteoarthritis |
| Q59356408 | Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort |
| Q37130666 | An essential receptor for adeno-associated virus infection. |
| Q55004770 | An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome. |
| Q37225659 | Antitumor activity and inhibitory effects on cancer stem cell-like properties of Adeno-associated virus (AAV) -mediated Bmi-1 interference driven by Bmi-1 promoter for gastric cancer |
| Q38645275 | Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion |
| Q89221788 | Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection |
| Q91970445 | Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects |
| Q40525635 | Assembly, Engineering and Applications of Virus-Based Protein Nanoparticles |
| Q39358118 | At Light Speed: Advances in Optogenetic Systems for Regulating Cell Signaling and Behavior |
| Q28087526 | Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment |
| Q36403441 | Bacteriophage Mediates Efficient Gene Transfer in Combination with Conventional Transfection Reagents |
| Q29248141 | Barriers to inhaled gene therapy of obstructive lung diseases: A review |
| Q92173264 | Bat adeno-associated viruses as gene therapy vectors with the potential to evade human neutralizing antibodies |
| Q38826202 | Beyond the brain: Optogenetic control in the spinal cord and peripheral nervous system |
| Q45873427 | Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity. |
| Q90104786 | Biomedical applications of mRNA nanomedicine |
| Q92761113 | Bone Morphogenetic Protein 4 Gene Therapy in Mice Inhibits Myeloma Tumor Growth, But Has a Negative Impact on Bone |
| Q38348602 | CRISPR genome engineering and viral gene delivery: a case of mutual attraction |
| Q37256205 | CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles |
| Q38670939 | CRISPR-Cas9 for medical genetic screens: applications and future perspectives |
| Q38848400 | CRISPR-Cas9 technology: applications and human disease modelling |
| Q92985826 | CRISPR-Cas9-Mediated Genome Editing Increases Lifespan and Improves Motor Deficits in a Huntington's Disease Mouse Model |
| Q38364993 | CRISPR-Cas9: a new and promising player in gene therapy |
| Q62937894 | CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency. |
| Q47161696 | CRISPR/Cas9 Genome-Editing System in Human Stem Cells: Current Status and Future Prospects. |
| Q101476290 | CRISPR/Cas9 as an antiviral against Orthopoxviruses using an AAV vector |
| Q59351134 | CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges |
| Q38680345 | CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy |
| Q64073285 | CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge |
| Q47100283 | CRISPR/Cas9-Mediated Deletion of CTG Expansions Recovers Normal Phenotype in Myogenic Cells Derived from Myotonic Dystrophy 1 Patients |
| Q39124456 | Cardiac gene therapy with adeno-associated virus-based vectors. |
| Q38345989 | Cartilage tissue engineering: recent advances and perspectives from gene regulation/therapy |
| Q47137633 | Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection |
| Q97423840 | Cerebral Organoids: A Human Model for AAV Capsid Selection and Therapeutic Transgene Efficacy in the Brain |
| Q98224409 | Challenges for Therapeutic Applications of Opsin-Based Optogenetic Tools in Humans |
| Q38787435 | Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site |
| Q26743393 | Clinical development of gene therapy: results and lessons from recent successes |
| Q45874360 | Combining Engineered Nucleases with Adeno-associated Viral Vectors for Therapeutic Gene Editing |
| Q33598920 | Construction and expression of a lentivirus expression vector carrying the VEGF165-EGFP fusion gene in breast cancer MCF-7 cells |
| Q37126292 | CrxRdy Cat: A Large Animal Model for CRX-Associated Leber Congenital Amaurosis |
| Q59354563 | Cryoprecipitate augments the global transduction of the adeno-associated virus serotype 9 after a systemic administration |
| Q92628591 | Current Trends in Viral Gene Therapy for Human Orthopaedic Regenerative Medicine |
| Q40264729 | Deficiency in Neuronal TGF-β Signaling Leads to Nigrostriatal Degeneration and Activation of TGF-β Signaling Protects against MPTP Neurotoxicity in Mice |
| Q37346447 | Design of virus-based nanomaterials for medicine, biotechnology, and energy |
| Q28077986 | Developing miRNA therapeutics for cardiac repair in ischemic heart disease |
| Q90361148 | Development of Versatile and Flexible Sf9 Packaging Cell Line-Dependent OneBac System for Large-Scale Recombinant Adeno-Associated Virus Production |
| Q52589810 | Different-Length Hydrazone Activated Polymers for Plasmid DNA Condensation and Cellular Transfection. |
| Q36270357 | Differential myofiber-type transduction preference of adeno-associated virus serotypes 6 and 9. |
| Q47690733 | Direct and efficient transfection of mouse neural stem cells and mature neurons by in vivo mRNA electroporation. |
| Q92757052 | Divergent engagements between adeno-associated viruses with their cellular receptor AAVR |
| Q28083324 | E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution |
| Q37607987 | Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo. |
| Q50187342 | Elixir of Life: Thwarting Aging With Regenerative Reprogramming |
| Q92635178 | Emerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy |
| Q47554736 | Emerging Issues in AAV-Mediated In Vivo Gene Therapy |
| Q26785927 | Engineered Viruses as Genome Editing Devices |
| Q52333355 | Engineered viral vectors for functional interrogation, deconvolution, and manipulation of neural circuits. |
| Q38854575 | Engineering AAV receptor footprints for gene therapy |
| Q89637735 | Engineering adeno-associated virus vectors for gene therapy |
| Q50888280 | Enhanced Delivery of Plasmid Encoding Interleukin-12 Gene by Diethylene Triamine Penta-Acetic Acid (DTPA)-Conjugated PEI Nanoparticles. |
| Q35635046 | Enhanced selective gene delivery to neural stem cells in vivo by an adeno-associated viral variant |
| Q89841932 | Enhancer-Driven Gene Expression (EDGE) Enables the Generation of Viral Vectors Specific to Neuronal Subtypes |
| Q37249326 | Enhancing Intracranial Delivery of Clinically Relevant Non-viral Gene Vectors |
| Q37736299 | Enhancing titres of therapeutic viral vectors using the transgene repression in vector production (TRiP) system |
| Q92349932 | Established and Emerging Strategies for Drug Delivery Across the Blood-Brain Barrier in Brain Cancer |
| Q41699665 | Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting |
| Q35952807 | Expression of CRISPR/Cas single guide RNAs using small tRNA promoters |
| Q57039874 | Extensive Transduction and Enhanced Spread of a Modified AAV2 Capsid in the Non-human Primate CNS |
| Q98906651 | FGF/FGFR signaling in health and disease |
| Q92283010 | Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors |
| Q51599772 | Flexible DNA junction assisted efficient construction of stable gene nanoparticles for gene delivery. |
| Q98178415 | Functions of Endothelial Cilia in the Regulation of Vascular Barriers |
| Q37113489 | Geminivirus-Mediated Genome Editing in Potato (Solanum tuberosum L.) Using Sequence-Specific Nucleases |
| Q57810479 | Gene Therapy Approaches to Biological Pacemakers |
| Q52743745 | Gene Therapy for Color Blindness. |
| Q37127238 | Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders |
| Q39011240 | Gene delivery to rat and human Schwann cells and nerve segments: a comparison of AAV 1-9 and lentiviral vectors. |
| Q38559511 | Gene therapy and peripheral nerve repair: a perspective. |
| Q33881920 | Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. |
| Q38607706 | Gene therapy returns to centre stage |
| Q38616032 | Gene therapy with an AAV vector expressing human IL-2 alters immune system homeostasis in humanized mice |
| Q37043485 | Genetic Manipulation of Brown Fat Via Oral Administration of an Engineered Recombinant Adeno-associated Viral Serotype Vector |
| Q36675277 | Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications |
| Q28066970 | Genome editing: the road of CRISPR/Cas9 from bench to clinic |
| Q41928233 | Genome engineering: a new approach to gene therapy for neuromuscular disorders. |
| Q52431359 | Genome scale screening identification of SaCas9/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection. |
| Q38681791 | Gold nanocages with dual modality for image-guided therapeutics |
| Q26782972 | HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis |
| Q36730743 | Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense |
| Q38864692 | High Efficiency CRISPR/Cas9-mediated Gene Editing in Primary Human T-cells Using Mutant Adenoviral E4orf6/E1b55k "Helper" Proteins |
| Q89448686 | High-Throughput In Vitro, Ex Vivo, and In Vivo Screen of Adeno-Associated Virus Vectors Based on Physical and Functional Transduction |
| Q97566829 | High-fidelity SaCas9 identified by directional screening in human cells |
| Q94502776 | Human Immune Responses to Adeno-Associated Virus (AAV) Vectors |
| Q45873745 | Immunity to CRISPR Cas9 and Cas12a therapeutics |
| Q40228879 | Improved gene delivery to adult mouse spinal cord through the use of engineered hybrid adeno-associated viral serotypes. |
| Q58745391 | In Vivo Genome Editing as a Therapeutic Approach |
| Q37045850 | In vivo gene editing in dystrophic mouse muscle and muscle stem cells |
| Q45884500 | In vivo gene therapy potentials of CRISPR-Cas9. |
| Q47153099 | In vivo genome editing improves motor function and extends survival in a mouse model of ALS. |
| Q47553772 | In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease |
| Q59096394 | In vivo reprogramming of wound-resident cells generates skin epithelial tissue |
| Q52648378 | Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases. |
| Q38732966 | Inflammation Improves Glucose Homeostasis through IKKβ-XBP1s Interaction |
| Q55090892 | Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique. |
| Q40875310 | Integration of AAV vectors and insertional mutagenesis |
| Q40120885 | Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial. |
| Q64040426 | Intravenous Infusion of AAV for Widespread Gene Delivery to the Nervous System |
| Q40082777 | Inverted Quasi-Spherical Droplets on Polydopamine-TiO2 Substrates for Enhancing Gene Delivery |
| Q35685009 | Isolation of novel sequences targeting highly variable viral protein hemagglutinin. |
| Q45872896 | Lancet Commission: Stem cells and regenerative medicine. |
| Q90152961 | Leber Congenital Amaurosis (LCA): Potential for Improvement of Vision |
| Q61807342 | Lecithin nano-liposomal particle as a CRISPR/Cas9 complex delivery system for treating type 2 diabetes |
| Q28831343 | Ligand-binding domains of nuclear receptors facilitate tight control of split CRISPR activity |
| Q41925391 | Liver-directed gene therapy for murine glycogen storage disease type Ib. |
| Q28085748 | Liver-targeted gene therapy: Approaches and challenges |
| Q64097102 | Local and systemic delivery of mRNA encoding survivin-T34A by lipoplex for efficient colon cancer gene therapy |
| Q40072904 | Local gene therapy durably restores vestibular function in a mouse model of Usher syndrome type 1G. |
| Q33715367 | Long-Term Assessment of AAV-Mediated Zinc Finger Nuclease Expression in the Mouse Brain. |
| Q91692021 | Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy |
| Q99565470 | Machine intelligence for nerve conduit design and production |
| Q35597374 | MicroRNAs and Cardiac Regeneration |
| Q58616125 | Mitochondrial glycerol 3-phosphate dehydrogenase promotes skeletal muscle regeneration |
| Q92510996 | Modulation of Sialic Acid Dependence Influences the Central Nervous System Transduction Profile of Adeno-associated Viruses |
| Q52584002 | Molecular biology and gene therapy for glycogen storage disease type Ib. |
| Q45323804 | Molecular design for recombinant adeno-associated virus (rAAV) vector production |
| Q92095428 | Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types |
| Q88540277 | Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing |
| Q38690435 | Nanoscale bio-platforms for living cell interrogation: current status and future perspectives |
| Q39233936 | Nanotherapy for Duchenne muscular dystrophy |
| Q38622440 | New and improved AAVenues: current status of hemophilia B gene therapy |
| Q40100060 | Next-generation AAV vectors for clinical use: an ever-accelerating race |
| Q28068242 | Non-Viral Nucleic Acid Delivery Strategies to the Central Nervous System |
| Q45871641 | Novel GP64 envelope variants for improved delivery to human airway epithelial cells. |
| Q38529941 | Obstacles and future of gene therapy for hemophilia |
| Q92146688 | Ocular gene therapy for choroideremia: clinical trials and future perspectives |
| Q41493938 | Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors |
| Q50333514 | Oligonucleotide conjugated multi-functional adeno-associated viruses. |
| Q52656550 | Optogenetic dissection of ictogenesis: in search of a targeted anti-epileptic therapy. |
| Q55656986 | Peptide-Based Supramolecular Hydrogels for Delivery of Biologics. |
| Q36406869 | Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy |
| Q60932114 | Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye |
| Q38818422 | Plasmodium meets AAV-the (un)likely marriage of parasitology and virology, and how to make the match |
| Q89916694 | Pre-arrayed Pan-AAV Peptide Display Libraries for Rapid Single-Round Screening |
| Q64067534 | Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats |
| Q34433586 | Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA |
| Q26752803 | Production and clinical development of nanoparticles for gene delivery |
| Q90183215 | Production of adeno-associated virus vectors for in vitro and in vivo applications |
| Q37621530 | Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies |
| Q37021623 | Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy |
| Q64101574 | Protein-based vehicles for biomimetic RNAi delivery |
| Q35652119 | RNA interference approaches for treatment of HIV-1 infection |
| Q47338076 | RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA. |
| Q60928892 | Rapid AAV-Neutralizing Antibody Determination with a Cell-Binding Assay |
| Q40735084 | Rapid, scalable, and low-cost purification of recombinant adeno-associated virus produced by baculovirus expression vector system |
| Q38776037 | Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia |
| Q39154043 | Recent advances in hemophilia B therapy |
| Q38843434 | Recent tissue engineering-based advances for effective rAAV-mediated gene transfer in the musculoskeletal system |
| Q36058890 | Recombinant AAV Vectors for Enhanced Expression of Authentic IgG. |
| Q40434024 | Recombinant Adeno-Associated Virus Serotype 6 (rAAV6) Potently and Preferentially Transduces Rat Astrocytes In vitro and In vivo. |
| Q92555262 | Recombinant Viral Vectors as Neuroscience Tools |
| Q33611961 | Release of Doxorubicin by a Folate-Grafted, Chitosan-Coated Magnetic Nanoparticle |
| Q40097476 | Relevance of assembly-activating protein for Adeno-associated virus vector production and capsid protein stability in mammalian and insect cells |
| Q34044390 | Riboswitch-mediated Attenuation of Transgene Cytotoxicity Increases Adeno-associated Virus Vector Yields in HEK-293 Cells |
| Q33608561 | Ring finger protein 43 associates with gastric cancer progression and attenuates the stemness of gastric cancer stem-like cells via the Wnt-β/catenin signaling pathway |
| Q54487829 | Role of Tetra Amino Acid Motif Properties on the Function of Protease-Activatable Viral Vectors. |
| Q91259654 | Safety and efficacy evaluations of an adeno-associated virus variant for preparing IL10-secreting human neural stem cell-based therapeutics |
| Q45875219 | Screening for Neutralizing Antibodies Against Natural and Engineered AAV Capsids in Nonhuman Primate Retinas |
| Q39122342 | Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma. |
| Q27324035 | Selective condensation of DNA by aminoglycoside antibiotics |
| Q34044724 | Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. |
| Q59352099 | Self-complementary and tyrosine-mutant rAAV vectors enhance transduction in cystic fibrosis bronchial epithelial cells |
| Q90178596 | Sequential two-step chromatographic purification of infectious poliovirus using ceramic fluoroapatite and ceramic hydroxyapatite columns |
| Q41551945 | Simple downstream process based on detergent treatment improves yield and in vivo transduction efficacy of adeno-associated virus vectors |
| Q90114574 | Single-Cell Transcriptome Analysis of Mouse Liver Cell-Specific Tropism and Transcriptional Dysregulation Following Intravenous Administration of AAVrh.10 Vectors |
| Q45325135 | Site Specific Modification of Adeno-Associated Virus Enables Both Fluorescent Imaging of Viral Particles and Characterization of the Capsid Interactome. |
| Q91652456 | Site-Directed Mutagenesis Improves the Transduction Efficiency of Capsid Library-Derived Recombinant AAV Vectors |
| Q64060862 | Splice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiency |
| Q35418235 | Spotlight on movement disorders: What optogenetics has to offer. |
| Q38894169 | State of the art: gene therapy of haemophilia |
| Q36398678 | Strategies to circumvent humoral immunity to adeno-associated viral vectors |
| Q83232387 | Structure of the gene therapy vector, adeno-associated virus with its cell receptor, AAVR |
| Q40180004 | Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion |
| Q33635361 | Sustained Inhibition of HBV Replication In Vivo after Systemic Injection of AAVs Encoding Artificial Antiviral Primary MicroRNAs |
| Q39179183 | Switching off pain at the source: is this the end for opioid pain relief? |
| Q38598783 | Synthetic multivalency for biological applications |
| Q89113558 | Synthetic switch-based baculovirus for transgene expression control and selective killing of hepatocellular carcinoma cells |
| Q57039821 | Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy |
| Q90971001 | Systemic AAV vectors for widespread and targeted gene delivery in rodents |
| Q38908933 | Systemic delivery of adeno-associated viral vectors |
| Q37028654 | Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model. |
| Q37577414 | TALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus |
| Q40131056 | TFEB-mediated activation of the lysosome-autophagy system affects the transduction efficiency of adeno-associated virus 2. |
| Q64266282 | Targeted Transgene Activation in the Brain Tissue by Systemic Delivery of Engineered AAV1 Expressing CRISPRa |
| Q40124877 | Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver |
| Q54217119 | The Assembly-Activating Protein Promotes Stability and Interactions between AAV's Viral Proteins to Nucleate Capsid Assembly. |
| Q39260698 | The CRISPR/Cas9 system: Their delivery, in vivo and ex vivo applications and clinical development by startups |
| Q90129514 | The Landscape of Early Clinical Gene Therapies outside of Oncology |
| Q41919375 | The Promise and Challenge of In Vivo Delivery for Genome Therapeutics. |
| Q96816785 | The delivery challenge: fulfilling the promise of therapeutic genome editing |
| Q26746647 | The emerging role of viral vectors as vehicles for DMD gene editing |
| Q47552046 | The evolution of CRISPR/Cas9 and their cousins: hope or hype? |
| Q40045823 | Therapeutic Gene Editing Safety and Specificity. |
| Q89858608 | Therapeutic genome editing in cardiovascular diseases |
| Q28087380 | Therapeutic genome editing: prospects and challenges |
| Q92997182 | Treatment of a Mouse Model of ALS by In Vivo Base Editing |
| Q45874163 | Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy |
| Q45872691 | Using an engineered glutamate-gated chloride channel to silence sensory neurons and treat neuropathic pain at the source |
| Q26741952 | Viral Vectors for Gene Therapy: Current State and Clinical Perspectives |
| Q40559495 | Viral infection: A key host receptor for AAV. |
| Q41643795 | Viral transduction of renin rapidly establishes persistent hypertension in diverse murine strains |
| Q36143310 | Viral vector-based improvement of optic nerve regeneration: characterization of individual axons' growth patterns and synaptogenesis in a visual target |
| Q38655270 | Virus-Derived Peptides for Clinical Applications |
| Q90012672 | Visualization of gene therapy with a liver cancer-targeted adeno-associated virus 3 vector |
| Q92020409 | biAb Mediated Restoration of the Linkage between Dystroglycan and Laminin-211 as a Therapeutic Approach for α-Dystroglycanopathies |
| Q38584497 | ceRNA in cancer: possible functions and clinical implications. |
| Q26741950 | mRNA-Based Therapeutics - Advances and Perspectives |
| Q26991956 | miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir |
Search more.